Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Advances in targeted therapy and immunotherapy for melanoma (Review)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis - ScienceDirect

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

MBM - Melanoma Brain Metastases

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma - Document - Gale OneFile: Health and Medicine

Cancers, Free Full-Text

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

PDF] Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - The Lancet Oncology

Cancers, Free Full-Text